Uterine papillary serous carcinoma

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 278-291

  Moore, Kathleen N ^a   Nickles Fader, Amanda ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

endometrial cancer; serous carcinoma; Uterine papillary serous carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL RADIOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; AGE; ANTIGEN DETECTION; ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENDOMETRIUM CANCER; FAMILY HISTORY; GENE OVEREXPRESSION; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; ONCOGENE NEU; OVARIECTOMY; OVARY CANCER; PAPILLARY CARCINOMA; PROGNOSIS; RACE; UTERUS CARCINOMA; UTERUS PAPILLARY SEROUS CARCINOMA; UTERUS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 79955554907     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318218c755     Document Type: Article

References (22)

1. Boruta DM, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
2. Fader AN, Boruta D, Olawaiye AB, et al. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010; 22:21-29.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17. (Pubitemid 13194678)
4. Fisher B, Costantino JP,WickerhamDL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652-1662. (Pubitemid 41672231)
5. Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. Section of Epidemiology: tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97:375-384. (Pubitemid 40425956)
6. Grushko TA, Filiaci VL, Mundt AJ, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;108:3-9. (Pubitemid 350299437)
7. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. Amorphologically diverse neoplasm with unitying clinicopathologic features. Am J Surg Pathol. 1992;16:600-610.
8. Bansal N, Herzog TJ, Brunner-Brown A, et al. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. Gynecol Oncol. 2008;111:208-212.
9. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751. (Pubitemid 38251372)
10. CruetzbergCL, vanPuttenWL, KoperPC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355: 1404-1411. (Pubitemid 30215963)
11. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009; 115:244-248.
12. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006; 100:349-354. (Pubitemid 43075268)
13. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22: 3902-3908. (Pubitemid 41079871)
14. Randall M, Filiaci V, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44. (Pubitemid 46630491)
15. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62:278-281. (Pubitemid 26274811)
16. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin +cisplatin versus doxorubicin+ 24-h paclitaxel+filgrastim in endometrial carcinoma: aGynecologicOncologyGroup study. Ann Oncol. 2004;15:1173-1178. (Pubitemid 39199303)
17. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22: 2159-2166. (Pubitemid 41095150)
18. Fader AN, Drake RD, O'Malley DM, et al. Platinum/taxane based chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119-2127.
19. FaderAN,Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: carboplatin/ paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009;112:556-562.
20. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543-552. [Epub December 23, 2008].
21. Thomas BM, Mariani A, Cliby WA, et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190-193. (Pubitemid 47575711)
22. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant therapy of patients with stage III and IV endometrial cancer: a Gynecologic Oncology group study. Gynecol Oncol. 2005;97:755-763. (Pubitemid 40824643)